 |
BiovaxID™ Promising for Follicular Lymphoma - cancerconsultants.com
For patients who were in remission following PACE chemotherapy
after 6 months and received BiovaxID vaccine: At a median
follow-up of 9.2 years - 45% of patients remained in
remission, overall survival rate is 95%. The median cancer-free
survival was 8 years.
|
|
AT-101 (aka gossypol) is a derivative of cottonseed oil in
clinical study for lymphoma - clinicaltrials.gov
|
|
“Fish
Oil Probably Doesn’t Fight Cancer” - http://thecheerfuloncologist.blogsome.com/
Now, there’s a misleading headline if ever I saw one - do
they mean that fish oil is too chicken to put up its dukes against
a cowardly band of sneering, narcissistic cancer cells? Is fish
oil destined to join its comrade laetrile
on the ash heap of ineffective cancer treatments?
|
|
Molecular pathogenesis of follicular lymphoma: a cross talk of
genetic and immunologic factors.
J Clin Oncol. 2005 Sep 10;23(26):6358-63. Review. PMID:
16155020
|
|
Caring (Really) for Patients Who Use Alternative Therapies for
Cancer - jco.org
"The reasons why people seek alternative therapies for
cancer are broad. Many seek out alternative therapy
when options for conventional therapy have been
exhausted. There is also the recognition that, for some
tumor systems, conventional therapy is of limited
effectiveness and that the side effects of chemotherapy, surgery,
and radiation are feared. For some tumor systems, no conventional
therapy exists and the standard therapy is participation in
phase I or phase II trials. Many patients perceive that the conventional
approach is emotionally or spiritually empty and provides
neither comfort nor solace."
|
| Caregiver stress resource page - PAL
|
| Bi-specific antibody study in Germany - clinicaltrials.gov
|
| No evidence for simian virus 40 DNA sequences in malignant
non-Hodgkin lymphomas.
Int J Cancer. 2006 Jan 15;118(2):498-504. PMID:
16052520
|
|
The Need for Harmonization in Biobanking to
Realize the Potential of 21st Century Medicine - Dr.
Anna Barker, NCI PDF
|
| How patients can help accelerate advanced tissue-based
research - http://biospecimens.cancer.gov/
|
| Cancer information and the Internet: Benefits and Risks - journeyofhearts.org
By Maurie Markman, MD
|
| Valsartan May Prevent CHOP-Induced Cardiotoxicity - Medscape
(free login req.)
|
| The role of genes in the development of non-Hodgkin's
lymphoma - news-medical.net
"... variations of individual DNA building blocks in genes
encoding for the cellular signaling molecules tumor necrosis
factor (TNF) and interleukin 10 (IL-10) increase the risk of
developing non-Hodgkin's lymphoma."
|
|
Biology and Management of Histologic Transformation of
Indolent Lymphoma - asheducationbook.org
"...chemotherapy is generally of limited benefit,
although a subset of patients are long-term survivors
following high-dose therapy and autologous stem cell
transplantation. The use of radioimmunotherapy and new
agents targeting specific lesions or aberrant pathways may impact
on the management of these aggressive diseases."
|
| Comparable results of umbilical cord blood and
HLA matched sibling donor hematopoietic stem cell transplant after
reduced-intensity preparative regimen for advanced hodgkin's
lymphoma.
Blood. 2005 Dec 29; PMID:
16384924
|
| From Cancer Patient to Cancer Survivor: Lost in Transition
- iom.edu
In the United States, half of all men and one-third of all women will develop cancer in their lifetimes. Advances in the detection and treatment of cancer, combined with an aging population, mean greater numbers of cancer survivors in the near future.
Despite the increase in survivors, however, primary care physicians and other health care providers often are not extremely familiar with the consequences of cancer, and seldom receive explicit guidance from oncologists. Furthermore, the lack of clear evidence for what constitutes best practices in caring for patients with a history of cancer contributes to wide variation in care.
|
| Nelarabine for T-cell lymphomas - nature.com
"intracellular ara-GTP level is predictive of response."
|
| Analysis of multiple biomarkers shows that
lymphoma-associated macrophage (LAM) content is an independent
predictor of survival in follicular lymphoma (FL).
Blood. 2005 Sep 15;106(6):2169-74. Epub 2005 Jun 2. PMID:
15933054 | related
articles
|
| Rituxan plus CHOP extends survival in advanced follicular
lymphoma - oncolink.upenn.edu
|
|
Where Next for Cancer Immunotherapy? - the-scientist.com
"The fact is that most work to date has been conducted in the absence of sufficient knowledge of the human immune response, particularly the response to cancer. Thus it is dangerously premature to conclude that cancer vaccines will not work when they have yet to be adequately conceived, supported, and coordinated."
|
|
A Phase I/II Study of TACI-Ig To Neutralize APRIL and
BLyS in Patients with Refractory or Relapsed Multiple Myeloma or
Active Previously-Treated Waldenström's Macroglobulinemia.
Session Type: Poster Session 770-II - ASH
2005
|
|
Multi-modality Therapies and Optimal Schedule of Antibodies:
Rituximab in Lymphoma as an Example
|
| Hematopathology Approaches to Diagnosis and
Prognosis of Indolent B-Cell Lymphomas - asheducationbook.org
PDF | Full
Text
(The advent of new technologies has contributed to improvements in
the diagnosis and classification of the non-Hodgkin lymphomas
(NHL)
|
| Subsequent therapy can be administered after
tositumomab and iodine I-131 tositumomab
for non-Hodgkin lymphoma. Cancer. 2005 Dec 16; PMID:
16362977
|
| Extranodal natural killer/T-cell lymphoma, nasal type.
Cancer. 2005 Dec 20;
In the management of nasal NK/T-cell lymphoma, the RT field
affected treatment outcomes. RT doses >/= 50 Gy resulted in
favorable local control. PMID:
16369986 | Related
articles
|
| ASH notes: Apoptosis and IAPs (rational drug
targets) - PAL
|
| NIH Launches Comprehensive Effort to
Explore Cancer Genomics! - PAL
|
|
A Phase II Trial of CHOP Chemotherapy Followed by
Zevalin
for Previously Untreated Elderly with high-risk Diffuse Large
B-Cell Lymphoma (DLBCL) - ASH
2005
|
|
DLBCL: Oral targeted drug, Enzastaurin, May Slow Progression :
Presented at ASH - docguide.com
|
|
Persistent organochlorine (PCB) chemicals in plasma and risk of non-Hodgkin's lymphoma.
Cancer Res. 2005 Dec 1;65(23):11214-26. PMID: 16322272
| Related
articles
|
|
THE TYRANNY OF POSITIVE THINKING - PDF
I got really depressed when people said I should think
positive. I thought, "If that's what I have to do to survive,
I'm never going to make it."
|
|
PCBs, furans may factor in risk of non-Hodgkin lymphoma - eurekalert.org
Scientists have found some additional evidence that environmental
exposure to polychlorinated biphenyls (PCBs) may be associated
with non-Hodgkin lymphoma, according to a study published in the
December 1 issue of Cancer Research.
|
| Successful Autologous Stem Cell Transplantation in Patients
with Non-Hodgkin's Lymphoma over the Age of 70 Years. - ASH
2005
|
|
CANCER VACCINES 2005: Barriers,
Endpoints, and Opportunities, Meeting Summary - cancerresearch.org
|
|
Preclinical:
Houston cancer center starts testing radio-wave theory - tmcnet.com
radio-wave in tandem with carbon nanotubes.
|
|
The Bad Seed - Rare stem cells appear to drive cancers -
sciencenews.org
"WRONG TARGET? Traditional cancer therapies (top) kill
rapidly dividing tumor cells (red) but may spare stem cells (blue)
that can give rise to a new tumor. In theory, killing cancer stem
cells (bottom) should halt a tumor's growth and perhaps even lead
to its disappearance."
Also see: The paradox of response and survival in cancer
therapeutics - bloodjournal.org
|
| Phase II Study of Oxaliplatin for Treatment of Patients With
Mucosa-Associated Lymphoid Tissue Lymphoma. J Clin Oncol. 2005 Nov
20;23(33):8442-6. PMID:
16293875
|
| ASH 2005 abstracts - requires free registration & login
- abstracts2view.com
|
| gossypol, a drug refined from cottonseed oil and previously
tried and abandoned as a male contraceptive could boost the
effectiveness of treatment for cancers as well. Targets
bcl-2 - med.umich.edu/opm
|
| Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms
- bloodjournal.org
|
| Complementary and Alternative Medicine and Cancer - plwc.org
Patrick Mansky, MD, National Center for Complementary and
Alternative Medicine (NCCAM)
November 1 – 30, 2005
|
|
Comorbidity Index Aids Stem Cell Transplant Choices - Medscape
(free login req.)
"reporting comorbidity data of the type used in this index
will likely become as important as defining cancer diagnosis,
disease stage, remission status, and other more familiar
prognostic variables."
|
|
AACR 2005 - Frontiers in Cancer Prevention Research - PDF
|
|
Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma:
a retrospective review of 1114 patients.
Leuk Lymphoma. 2005 Dec;46(12):1715-20. PMID:
16263573
|
|
The Environmental Causes of Cancer ~ Why We Can't Prevent
Cancer - By PETER MONTAGUE - counterpunch.org
(scroll down to second article. It's provocative. )
|
|
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38
(BL22) in patients with B-cell malignancies.
J Clin Oncol. 2005 Sep 20;23(27):6719-29. Epub 2005 Aug 1. PMID:
16061911
|
|
Value of oxaliplatin treatment in heavily pretreated patients
with non-Hodgkin's lymphoma.
Leuk Lymphoma. 2005 Oct;46(10):1437-40. PMID:
16252433
|
|
Treatment strategies in follicular lymphomas: current status
and future perspectives.
J Clin Oncol. 2005 Sep 10;23(26):6394-9. Review. PMID:
16155025
|
|
Radiofrequency ablation of lymphoma. Blood. 2005 Oct 27; PMID:
16254135
|
|
Dendritic cells in autologous hematopoietic stem cell
transplantation for diffuse large B-cell lymphoma: graft content
and post transplant recovery predict survival. Bone Marrow
Transplant. 2005 Oct 10; PMID:
16247431
|
|
New research links infection with Ocular adnexal lymphoma - msnbc.msn.com
|
|
Study raises hopes antibiotics may be an alternative to chemo,
radiation
|
|
Immunotherapy of malignant diseases: cancer
therapy beyond chemotherapy - roche.com
PDF
Very nice primer on immunity and immunotherapy.
|
| Zevalin update: Biogen Idec and FDA notified
healthcare professionals of revision to BOXED WARNINGS, WARNINGS,
and ADVERSE REACTIONS sections of the Prescribing Information to
describe severe cutaneous (skin) or mucocutaneous (mucosal
linings) reactions, some with fatal outcome, that have been
reported in association with the Zevalin therapeutic regimen in
the post-marketing experience. - fda.gov/medwatch |
medpagetoday.com
|
| GSK's Arranon (nelarabine)
Response Rates Likely To Predict Clinical Benefit In
Leukemia/Lymphoma - fdaadvisorycommittee.com
|
| Dr. Czucman on Treatments for follicular NHL - nhlupdate.com
|
| New Treatment Options Have Changed the Survival of Patients
With Follicular Lymphoma.
J Clin Oncol. 2005 Oct 17; PMID:
16230674 | Related
articles
|
| Secondary Amenorrhea [no menstrual periods] After Hodgkin's
Lymphoma Is Influenced by Age at Treatment, Stage of Disease,
Chemotherapy Regimen, and the Use of Oral Contraceptives During
Therapy: A Report From the German Hodgkin's Lymphoma Study Group.
J Clin Oncol. 2005 Oct 20;23(30):7555-64. PMID:
16234521
|
| Gamma camera scans and pretreatment tumor volumes as
predictors of response and progression after Y-90 anti-CD20
radioimmunotherapy. Int
J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):194-201. PMID:
16111589
|
| Cancer patients conceal alternative meds - nlm.nih.gov
|
|
Pillows - a hot bed of fungal spores (October 14, 2005) - manchester.ac.uk
|
|
"Researchers at The University of Manchester funded by
the Fungal Research Trust have discovered millions of fungal
spores right under our noses - in our pillows.
|
|
Aspergillus fumigatus, the species most commonly found in the
pillows, is most likely to cause disease; and the resulting
condition Aspergillosis has become the leading infectious cause of
death in leukaemia and bone marrow transplant patients. Fungi also
exacerbate asthma in adults."
|
| B-type natriuretic peptide (BNP) levels in patients
receiving high-dose chemotherapy can detect those at risk of late cardio toxicity
- medscape.com
(free login req.)
|
| Low Histologic Grade Follicular Lymphoma With High
Proliferation Index: Morphologic and Clinical Features. - ajsp.com
|
| Autoimmune Disease Is a Risk Factor for the Development of Non-Hodgkin's Lymphoma
- rheum.com
|
| Rare Immune Cell Is Key to Transplant Cancer-Killing Effect
- newswise.com
|
|
Method of laser activated nano-thermolysis for elimination of
tumor cells [purging harvested stem cells].
Cancer Lett. 2005 Sep 30; PMID:
16202512 | Related
articles
|
|
Immunochemotherapy with rituximab and temozolomide for central
nervous system lymphomas. Cancer. 2004 Jul 1;101(1):139-45. PMID:
15221999 | Related
articles
|
|
Annual Report to the Nation Finds Cancer Death Rates Still on the Decline
By NIH/National Cancer Institute Oct 5, 2005, 09:02 - foodconsumer.org/
"... Overall cancer incidence rates (the rate at which new cancers are diagnosed) for both sexes have been stable since 1992. Incidence rates were stable in men from 1995 to 2002 and increased 0.3 percent annually in women since 1987 to 2002.
* The persistent increase in overall cancer incidence rates for women can be attributed to increases in rates for breast and six other cancers:
non-Hodgkin lymphoma, melanoma, leukemia, and thyroid, bladder and kidney cancer.
"
|
|
Chemotherapy and Rituxan® Followed by Autologous Stem Cell
Transplant May Improve Survival of Patients with Mantle Cell
Lymphoma
|
|
"French researchers have reported that the addition of
Rituxan® (rituximab) to induction chemotherapy followed by
autologous stem cell transplantation improved overall survival of
patients with mantle cell lymphoma without added toxicity."
[Lay comment: since this was not a randomized study, selection
bias (picking ideal patients) could be a reason for the better
results - relative to historical controls.]
|
|
Long-term remission of blastic natural killer-cell lymphoma
after autologous peripheral blood stem-cell transplantation. Am J
Hematol. 2005 Oct;80(2):124-7. PMID:
16184583 | Related
articles
|
|
NK cell adoptive immunotherapy - Andrea Velardi - bloodjournal.org
In this issue of Blood, Miller and colleagues present data on the
administration of haploidentical NK cells to cancer patients. They
identify a feasible and safe method for in vivo NK cell expansion
and clinical efficacy.
|
|
IMMUNOTHERAPY AND CHEMOTHERAPY — A PRACTICAL PARTNERSHIP - nature.com
pdf
|
|
The impact of age and gender on biology, clinical features and
treatment outcome of non-Hodgkin lymphoma in childhood and
adolescence. Br J Haematol. 2005 Oct;131(1):39-49. PMID:
16173961
|
|
Antibiotics
Effective in Treatment of MALT Lymphoma - cancerconsultants.com
|
|
THE PROMISE OF CANCER VACCINES - nature.com
Eli Gilboa, The Center for Cellular and Genetic
Therapies,
Duke University Medical Center, Durham, North Carolina 27710, USA.
|
| Treatment
[Sequential high dose chemotherapy followed by SCT] Promising for
Relapsed Aggressive Non-Hodgkin’s Lymphoma - cancerconsultants
|
| Data from Phase 3 Trial of Genasense(R) Confirm Extended
Durability of Remission and Benefit in Patients with Relapsed or
Refractory Chronic Lymphocytic Leukemia - prnewswire.com
|
| CLL discovery: A new and unusual class of genes (miR-15 and
miR-16) plays an important role in the development of chronic
lymphocytic leukemia (CLL), according to new research here. At the
same time, these genes may provide a new form of therapy for the
disease - sciencedaily.com
|
| To mark the second World Lymphoma Awareness Day (WLAD),
50 people from
15 countries are preparing to tell their stories of how lymphoma
has
affected their lives. - yahoo.com/prnews
|
| Drug delivery: A tiny timely vehicle - nature.com
| Also see PAL
"the nanocells containing both drugs resulted in the lowest
systemic
toxicity of all of the treatments. This is probably because the
cytotoxic
agent is localized to the tumour so effectively"
|
| Study Finds Overall Health and Quality of Life Intact 10
Years After Stem-Cell Transplantation - prnewswire.com
|
| FDG-PET after two cycles of chemotherapy predicts treatment
failure and progression-free survival in Hodgkin Lymphoma. Blood.
2005 Sep 8; PMID:
16150944
|
| Skewed T cell differentiation in indolent non-Hodgkin's
lymphoma patients reversed by ex-vivo T cell culture with {gamma}c-cytokines.
Blood. 2005 Sep 8; PMID:
16150945 | Related
articles
|
| Arranon (Nelarabine) Response
Rates Likely To Predict Clinical Benefit In T-cell
Leukemia/Lymphoma - fdaadvisorycommittee.com
*
|
| Revlimid (lenalidomide) Phase
II Data Sufficient For Full Approval In Myelodysplastic
Syndromes, Cmte. Says - fdaadvisorycommittee.com
*
|
| Medical Imaging Goes Preclinical - dddmag.com
Researchers are looking to imaging tools like MRI and PET to help bridge the gap between discovery and clinical end points
|
| Aplidin(R) (plitidepsin), PharmaMar's novel marine-derived
anti-tumour agent, originally isolated from the tunicate Aplidium
albicans. - itnews.it
|
| Clinical trial of interest: Lenalidomide With or Without
Rituximab - ClinicalTrials.gov
Condition: CLL
 TOPIC SEARCH on Lenalidomide
AND Rituximab
|
|
Bexxar Following Fludarabine Produced Response in 100% of
patients [first line] - med.cornell.edu
|
|
Health Canada approves new targeted radioimmunotherapy ~
Bexxar(TM) Receives Approval to Treat Follicular Non-Hodgkin's
Lymphoma - newswire.ca
|
|
Levofloxacin Prevents Infection in Neutropenic Cancer Patients
- cancerpage.com
|
|
Current Approach to Diagnosis and Management of Chronic
Lymphocytic Leukemia ~ mayoclinic
|
|
Phase I study of spirogermanium given daily - jco.org
"Spirogermanium, an azaspirane compound, has recently had
limited clinical trials using a schedule of intravenous
injection one to three times every week. The
observation of clinical antitumor activity and *lack of myelosuppression*
prompted us to investigate further the clinical effects of spirogermanium
administered on various schedules." ... "Of the 44
assessable patients, 3 demonstrated a partial response
and 3 had minor tumor regression; all responses
occurred in lymphoma patients."
Clinical
Trial - Cancer.gov
|
| About Lymphoma in the Bone Marrow - New
PAL topic
|
| Chimera: from bane to blessing - bloodjournal.org
"New data suggest that a mild preparative regimen of
antibodies that block CD40 ligand and deplete host NK
cells may make allogeneic hematopoietic stem cell
transplants safe, establish long-term immunologic
tolerance, and broaden the applicability of cord blood
as a source of stem cells by making engraftment more
efficient."
|
| Survival with AIDS-Related NHL Predicted by CD4 Cell Count
and International Prognostic Index - cancerconsultants.com
|
| BioCryst Initiates Fodosine(TM) Oral Phase II Clinical Trial
in Patients With Advanced, Fludarabine-Refractory Chronic
Lymphocytic Leukemia (CLL) - prnewswire.com
|
| Temsirolimus
Promising for Treatment of Mantle Cell Lymphoma, and other cancers
- cancerconsultants.com
|
| MALT: The importance of monitoring for H. pylori
re-infection - eurekalert.org
"The significance of the described work is that gastric
lymphoma progresses more rapidly upon secondary infection. Because
resting B cells are left behind following antibiotic treatment,
re-infection by
H. pylori promotes the existing B cells to progress quickly into
tumors. Therefore, it is important that treated patients be
carefully monitored for H. pylori re-infection."
|
| Immunodiagnostics Shape Immunotherapeutics for Improved Cancer Care CME
Disclosures, Hossein Jadvar, MD, PhD - Medscape
There is rapid emergence of recombinant and antibody-based reagents, which specifically target biomarkers of disease. Radiolabeling of antibodies has provided the means for cancer imaging and therapy.
|
| The Nurses Guide to Prescription Drugs - starting with A - healthdigest.org/
|
|
Continuing challenges in childhood non-Hodgkin's lymphoma.
Br J Haematol. 2005 Aug;130(4):480-8. PMID:
16098061
|
|
Approaches to treating non-Hodgkin's Lymphoma:
Dr Leonard - nhlupdate
| Dr Coleman - nhlupdate
| Dr Zelenetz nhlupdate
Dr. Cheson - nhlupdate
| Dr Czuczman - nhlupdate.com
| Dr Armitage - nhlupdate.com
Audio files for patients: John Leonard, Mitchell Smith, Brad Kahl
- nhlupdate.com
|
| Vaccine Could Combat Cancer [Lymphoma] - ivanhoe.com
They treated 26 patients diagnosed with mantle cell lymphoma
with a B-cell depleting treatment followed by an experimental
vaccine.
|
|
Survival of Patients with Follicular Lymphoma is Improving - cancerconsultants.com
|
|
Elderly or frail NHL Patients Not Receiving Aggressive
Chemotherapy May Benefit from Less Intensive Treatment - cancerconsultants.com
|
|
Researchers make 'embryonic-like' stem cells from umbilical
cord blood - newscientist.com
|
|
Two EVENTS - plwc.org
* August 30, 2005, 2:00 – 3:00 PM ET
Nutrition and Cancer Tim Byers, MD, MPH (left)
Colleen Gill, MS, RD (right)
University of Colorado at Denver and Health Sciences Center
* September 12, 2005, 2:00 – 3:00 PM ET
Understanding Lymphoma
Sandra J. Horning, MD
ASCO President 2005 - 2006 | Stanford University Medical Center
|
|
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide
synthase. Cancer Res. 2005 Jun 15;65(12):5027-30. PMID: 15958544
"These findings provide a new rationale at the molecular
level for the
combination of chemotherapy and immunotherapy in cancer
treatment."
|
|
Long-term outcome after radiotherapy alone for
lymphocyte-predominant Hodgkin lymphoma.
Cancer. 2005 Aug 10; PMID:
16094666
|
|
Relevant to CNS Lymphoma: Enhanced chemotherapy
delivery by intraarterial infusion and blood-brain barrier
disruption in malignant brain tumors: the Sherbrooke experience.
Cancer. 2005 Jun 15;103(12):2606-15. PMID:
15880378 | Related
articles
|
|
Specific Regimen Influences Risk
of Myelodysplasia After Lymphoma Treatment - Medscape
Aug 2005: "... none of the 76
patients with previously untreated, advanced-stage follicular
large granular non-Hodgkin lymphoma (LG-NHL) who received [bexxar]
as initial therapy developed t-MDS or t-AML over the 4.6 years of
median follow-up.
"While longer follow-up is needed,"
the authors conclude, "these results suggest that
radioimmunotherapy will, with acceptable toxicity, take its place
among the more effective therapies for LG-NHL." -
|
| From the analyst's couch ~ Therapeutic cancer vaccines - nature.com
|
| Tobacco and alcohol consumption and risk of lymphoma: Results of a population-based case-control study in Germany. Int J Cancer. 2005 Aug 3;
PMID: 16080191
|
| A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.Blood. 2005 Aug 4;
PMID: 16081686
| Related
articles
|
| Cytomegalovirus pneumonia in patients with lymphoma. Cancer.
2005 Aug 2; - PMID:
16078263
|
| Researchers Explore Possible Applications of Nanotechnology
in Cancer Treatment - mdanderson.org
|
| Eloxatin® Active in Patients with Refractory
Non-Hodgkin’s Lymphoma - cancerconsultants.com
|
| Encouraging New Technology:
Standford Scientists develop nanotech-laser treatment that kills
cancer cells without harming healthy tissue - innovations-report.com/
|
| Specific Regimen [FND] Influences Risk of Myelodysplasia
After Lymphoma Treatment - Medscape
(free login req.) or ASCO
|
| 17-AAG for CLL: An Important New
Trial Has Been Announced ~ by Chaya Venkat - CLLtopics
Very nice and balanced description of a new targeted agent for
CLL and possibly other lymphomas
|
| PET Scan More Accurate Predictor of Outcome in [aggressive]
Non-Hodgkin’s Lymphoma - cancerconsultants.com
|
|
Meet the Professors - a provocative discussion among experts
regarding first treatment options for
advanced follicular lymphoma - meettheprofessors.com
|
|
An Internet-Based Cancer Clinical Trials Matching Resource
- jmir.org
James M Metz1, MD; Carolyn Coyle1, RN, MSN, AOCN; Courtney
Hudson2, MBA;
Margaret Hampshire1, RN, BSN, OCN
|
|
|
| Cyclophosphamide, Cytarabine and Methotrexate Regimen
Followed by Stem Cell Transplantation Effective for Refractory
[or relapsed aggressive] Lymphomas - cancerconsultants.com
|
| Researchers at CSHL have shown that RNA interference (RNAi)
can be used to set the level of gene activity in stem cells on
"low," "medium," or "high." - cshl.edu
|
|
|
| Personalized Approach to Cancer
Genitope hopes its custom-made vaccines for lymphoma will lead to extended remissions.
By Denise Gellene, Times Staff Writer - latimes.com
|
| Immunomodulators for Inflammatory Bowel Disease Raise
Lymphoma Risk - medscape.com
"Treating inflammatory bowel disease (IBD) with
azathioprine or 6-mercaptopurine (6-MP) increases the risk of
lymphoma by about fourfold, according to a report in the August
issue of Gut. Still, the absolute risk of this malignancy is small
and, for most patients, the benefits of these agents outweigh the
risks."
|
| Nanotechnology in Cancer Spotlighted at NSTI Nanotech 2005 -
nano.cancer.gov/
"Nanoparticles, ... can have multiple functionalities that can provide detailed information on numerous disease processes simultaneously. Similarly, nanoscale devices can deliver multiple therapeutic agents to a tumor in order to simultaneously attack multiple points in the pathways involved in cancer. Nanotechnology is also generating in vivo biosensors that have the capability of detecting and pinpointing the location of tumors and metastatic lesions that are far smaller than those detectable using conventional technologies. Detecting cancer before it spreads completely changes the game when it comes to treating cancer, since non-metastatic cancer is rarely fatal. Nano-enabled in vivo sensors may also provide rapid information on whether a given therapy is actually working as expected, and targeted nano-based therapeutics that hone in on tumors stand to increase the efficacy of drugs while dramatically reducing potential side effects."
|
| Infectious disease associations in indolent lymphoma
(follicular, FL and non-follicular, nFL): Developing a lymphoma
prevention strategy. - ASCO
2004
|
| Induction of tumor NK-cell immunity by anti-CD69 antibody
therapy. Blood. 2005 Jun 1;105(11):4399-406. Epub 2005 Feb 3. PMID:
15692061 | Related
articles
|
| ASK ANNIE In Job Interviews, Should I Say I'm a Cancer Survivor?
- fortune.com
|
| Researchers Learn More About Secondary Cancers After Non-Hodgkin’s Lymphoma
- cancerconsultants.com
" Researchers concluded that secondary cancers after NHL are
often treatment-related, but other sources, such as immune
suppression and environmental exposures, may also play a role in
the development of secondary cancers and malignancies."
|
| Two New Studies on Aspartame and Diet Drinks Confirm Source of Obesity, Cancer/Malignant Brain Tumor
pressbox.co.uk
|
| Preventing
vincristine administration errors! - jcaho.org
"This
tragedy is so preventable—yet there have been many cases
reported in the media of patients being injected with vincristine
intrathecally," says Michael R. Cohen, R.Ph., M.S., Sc.D.,
president, ISMP. "These cases are especially tragic because
the patient experiences paralysis and a slow and extremely painful
deterioration, which in nearly all cases results in death."
|
| Recombinant, tumour-derived idiotype vaccination for
indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert
Opin Biol Ther. 2005 Jun;5(6):841-52. PMID:
15952914 | Related
articles
|
| Tandem SCT: Autologous transplantation followed closely by
reduced-intensity allogeneic transplantation as consolidative
immunotherapy in advanced lymphoma patients: a feasibility study.
Bone Marrow Transplant. 2005 Jul 4; PMID:
15995712
|
| A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab
tiuxetan in Combination with High-Dose Etoposide and
Cyclophosphamide Followed by Autologous Stem Cell Transplant in
Patients with Poor-Risk or Relapsed Non-Hodgkins Lymphoma (NHL).
Blood. 2005 Jul 7; PMID:
16002426
No response data, but ... "We conclude that high-dose
(90)Y ibritumomab tiuxetan can be combined safely with high-dose
etoposide and cyclophosphamide without increase in
transplant-related toxicity or delayed engraftment."
|
| Lay discussion on potential merits of adding Neupogen to
rituxan - clltopics.org
|
| Therapeutic vaccination against murine lymphoma by
intratumoral injection of naive dendritic cells.
Cancer Res. 2005 Jul 1;65(13):5958-64. PMID:
15994975 | Related
articles
|
|
|
| National Bio-informatics Network - proposed graphic
representation - PDF
|
|
"The patient is waiting" - patient perspectives on
toxicity and the need for innovation - PAL
|
|
Activation of Infiltrating Cytotoxic T Lymphocytes and Lymphoma Cell Apoptotic Rates in Gastric MALT Lymphomas
Differences between High-Grade and Low-Grade Cases
Massimo Guidoboni*, Claudio Doglioni, Licia Laurino, Mauro Boiocchi* and Riccardo Dolcetti*
From the Division of Experimental Oncology 1,* - amjpathol.org
|
|
New Approach Works Against Leukemia, Lymphoma ~ Using
stem cells from **two** umbilical cords a breakthrough for
adult patients - drkoop.com
|
| Review article on bexxar - us.elsevierhealth.com
(full text) Dec 2005
|
| Italian
Study Links Tobacco Use to Development of [follicular] NHL - cancerconsultants.com
"They reported a 50 percent increased risk for 16-33
pack-years and an 80 percent increased risk with 34 pack years or
greater. There was no increased risk for the other NHL subtypes.
In the second study, data on over 6,500 cases of NHL showed only
an increase incidence of follicular NHL and not other cell
types."
|
|
Improved Survival of Follicular Lymphoma Patients in the
United States.
J Clin Oncol. 2005 Jun 27; PMID:
15983392
|
|
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for
Relapsed Mantle Cell Lymphoma.
J Clin Oncol. 2005 Jun 27; PMID:
15983389
|
|
Antibodies to JC and BK viruses among persons with non-Hodgkin
lymphoma.
Int J Cancer. 2005 Jun 28; PMID:
15986438
|
|
New study finds how cells with damaged DNA alert the immune
system - eurekalert.org
|
| Poll Finds Many Americans Believe Cancer Myths
An American Cancer Society survey finds up to half of Americans mistakenly believe surgery can spread cancer, and more than one in four thinks a cure for cancer already exists but is being held back by a profit-driven industry. Results of the survey are published in the August 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The authors say it shows the American public is significantly ill-informed about cancer, and that most overestimate how much they know.
Sociodemographic determinants of cancer treatment health literacy
- full
text interscience.wiley.com
|
| City of Hope performs world's first total marrow irradiation procedure
- pasadenastarnews.com
"TomoTherapy combines two different technologies, a CT scan
and precisely directed radiation. The CT scan creates a three-
dimensional computer model of the patient's internal anatomy. The
scan allows doctors to determine the daily changes to a patient's
body that could influence the target area."
|
| Summary of 9th International Conference on Malignant Lymphoma
(ICML) - pdf
|
| Zevalin May Be a Second-Line Treatment Option for Patients
Not Eligible for Stem Cell Transplantation - mysan.de
|
|
Q & A with Dr. Zinzani concerning treatment options for
follicular - lymphoma.ca
|
|
Leukine boosts rituximab effectiveness against non-Hodgkin's lymphoma
- pharma-business-review.com
According to researchers at The University of Texas M. D. Anderson Cancer Center, the colony stimulating factor Leukine appears to improve the efficacy of rituximab in treating the most common form of non-Hodgkin's lymphoma.
[in small single arm study]
|
|
Tumour Microenvironment and Host Inflammatory Response
Identified as Defining Features in Diffuse Large B-Cell Lymphoma:
Presented at ICML - docguide.com
|
|
Limited Stage Follicular Lymphoma Might Be Curable: Presented
at ICML - docguide.com
|
| A Vision for the National Cancer Program in the United States
Andrew C. von Eschenbach - medscape.com
|
| Health Canada approved Zevalin. You can view the Notice of
Compliance (NOC) which is what they issue when they have approved
a new drug. - hc-sc.gc.ca
BC has approved funding for it, but you would have to read their
policy paper more closely. bccancer.bc.ca
|
| "Chronic GvHD: The Next Frontier in Transplantation
Research" June 2005 - presentations and working group
documents - palladianpartners.com/gvhd/docs
|
| Single Injection Pegfilgrastim Supports Delivery of
Dose-Dense Chemotherapy - pslgroup.com/
|
| ADD Drug Shows Effectiveness Against "Chemobrain" - nci.nih.gov
Also see Focalin, a refined formulation of Ritalin (d,l-methylphenidate
HCl) - centerwat |
